Galderma Research & Development

Galderma Holding Sa

Chugai Seiyaku Kabushiki Kaisha

Galderma S.a.

Nabil Kerrouche

Jean-Charles Dhuin

Stéphanie Arsonnaud

Pascale Soto

Ryosuke Mihara

Keiko Hirokawa

Philippe Martel

Fabien Audibert

Disclosed herein are methods for selectively treating atopic dermatitis (AD) in a subject having skin excoriations, pharmaceutical compositions for use in the treatment of atopic dermatitis in a subject having skin excoriations, uses of nemolizumab or an equivalent thereof in the manufacture of a medicament for the treatment of atopic dermatitis in a subject having skin excoriations, and methods of identifying a subject having atopic dermatitis that is likely to respond to nemolizumab treatment or an equivalent thereof.

Nemolizumab in the treatment of atopic dermatitis with moderate to severe excoriation

The present invention relates to a combination of ivermectin and brimonidine for use in the treatment and/or the prevention of moderate to severe rosacea, preferably by topical administration of a 1% ivermectin cream and 0.33% brimonidine gel.

Use of ivermectin and brimonidine in the treatment and/or prevention of moderate to severe rosacea

A novel maintenance therapy regime/regimen for the treatment of acne related diseases includes administering an oral antibiotic with a topical fixed-dose combination of a retinoid, such as adapalene, and an anti-bacterial agent, such as benzoyl peroxide.

Maintenance therapy regime/regimen for the treatment of acne

A novel therapy regime/regimen for the treatment of acne related diseases includes administering a topical fixed-dose combination of a retinoid and an anti-bacterial agent, such as BPO, to a course of oral antibiotic therapy.

Concurrent therapy regime/regimen for the treatment of acne related diseases

Growing community of inventors

Le Rouret, France

Nabil Kerrouche